176 results
Page 2 of 9
8-K
EX-99.1
3p30tf
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-10.1
mqsaas28eqmvqvdr 31
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.2
ytv 0keau22ub
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.4
4wa3w7lea7 lnzyg
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
qykuu45qmmr2rjk38kk
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
3jh adaenzr
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
424B3
e4j8ceys8qhr9f2wt6
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
EX-23.1
p9uh4pnq853i8al3s1
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4/A
dmwo pfc1d2dn
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4/A
EX-23.2
8qe83uk
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
EX-23.1
xugwy k0dswmmmzk1d
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
S-4
l8molcj
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
S-4
EX-23.2
hrdqps5l o9t
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-99.1
r5vuwqwmj s2r
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
8if6kib5y76 h0q
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am